it is all in the timing

They did it again ... releasing what can be a great announcement a FRIDAY AFTERNOON JUST BEFORE 4PM !!!

How about that ?? Hopefully, the data presented at this conference this week-end will lead to other papers released next week ...


Presentation of Data on Progen's Cancer Epigenetic Targets Platform

BRISBANE, Australia, May 30 /PRNewswire-FirstCall/ -- (ASX: PGL;
Nasdaq: PGLA) New data on Progen's cancer epigenetic targets program will be presented tomorrow at the American Association for Cancer Research(AACR) Epigenetics Meeting in Boston by Progen's collaborators at the Johns Hopkins University.

The data to be presented demonstrates that compounds in Progen's existing preclinical cancer epigenetics program functionally inhibit the activity of LSD-1, an exciting new epigenetic cancer target which, if inhibited, may activate genes that protect against tumor development. These
LSD-1 inhibitors are the first to demonstrate effective re-expression of aberrantly silenced genes by targeting this recently discovered cancer gene regulator.

Dr. Laurence Marton, Progen's Chief Scientific Officer, said, "We have discovered from in vitro testing that by inhibiting LSD-1 with this new class of compounds we can reactivate genes that normally suppress cancer and are deactivated in cancer-triggering processes. We are now extending these studies to animal cancer models to determine if we can inhibit the growth of tumors."

"This is a new frontier in cancer treatment and we are excited to be entering this novel therapeutic area", said Dr. Marton.

Progen already has preliminary preclinical efficacy data for many of its cancer epigenetics compounds, and is planning to move additional related compounds into further efficacy, safety and pharmacokinetic models within the coming months.

About the AACR Cancer Epigenetic Special Conference: The AACR special conference on cancer epigenetics assembles prominent investigators in the field to discuss recent advances in this rapidly moving area. It provides a
unique forum to review the remarkable progress in this area over the past few years, and provides a glimpse of where the field is moving, with a strong emphasis on translational epigenetics research.